

**PCR-/NAT *Mycoplasma pneumoniae*
 (RV 541) Mai 2012**



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.
Sample composition and expected results.

	<i>Erwartet / expected</i>		<i>Probenzusammensetzung / Sample composition</i>
1215411	++	61	<i>Mycoplasma pneumoniae</i> (~ 10 ⁵ genome copies/mL)
1215412	∅	62	<i>Ureaplasma urealyticum</i> (~ 1x10 ² CFU/mL)
1215413	+	61	<i>Mycoplasma pneumoniae</i> (~ 10 ⁴ genome copies/mL)
1215414	∅	62	<i>Escherichia coli</i> K12

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.
Absolute numbers of reported individual results.

<i>n</i> = 102	Probennummer (Sample no.)				Inhibition				
Befund <i>Result</i>	1215411	1215412	1215413	1215414	1215411	1215412	1215413	1215414	
Positiv	102	3	101	0	n.d.	0	0	0	0
Negativ	0	98	0	102	nein <i>no</i>	102	102	102	102
Fraglich <i>Questionable</i>	0	1	1	0	ja <i>yes</i>	0	0	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwendern verschiedener Methoden.

Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number *)	NAT richtig positiv <i>True positive results</i>			NAT richtig negativ <i>True negative results</i>		
	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%
LightMix <i>M.pneumoniae</i> [20] (n = 10)	20	20 / 20	100	20	20 / 20	100
Qiagen <i>M.pneumoniae</i> [21] (n = 3)	6	6 / 6	100	6	4 / 6	100
Minerva Venor Mp [22] (n = 1)	2	2 / 2	100	2	2 / 2	100
Commercial assay / kit [27] (n = 34)	68	68 / 68	100	67	67 / 67 §	100
In house PCR assay [28] (n = 51)	101	101/101 §	100	100	100 / 102	98
Andere / k.A. / other [29] (n = 3)	6	6 / 6	100	5	5 / 6	83

§ Due to reporting questionable results, the number of true results (denominator in the "relative" column) have been reduced